Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Vyvgart Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
During the historical timeframe, growth stemmed from a deeper comprehension of autoimmune disease processes, the authorization of new biologic treatments, a rise in the diagnosis frequency of gMG, the broadening of specialized neurological services, and the accessibility of sophisticated antibody treatments.
Prominent trends expected in the forecast period involve a broader embrace of fcrn inhibitor therapies, an increasing emphasis on targeted treatments for autoimmune conditions, the expanding clinical application of antibody reduction mechanisms, a growing need for personalized immunotherapy solutions, and a heightened focus on managing diseases over the long term.
Get A Free Sample Report With In-Depth Market Insights:
Vyvgart Market Growth Drivers: What’s Behind The Acceleration?
The anticipated expansion of the vyvgat market is intrinsically linked to the growing occurrence of autoimmune diseases. These conditions manifest when the body’s immune system erroneously attacks its own healthy cells and tissues, perceiving them as foreign or harmful. The rise in autoimmune disorders is largely attributed to a combination of genetic predisposition, environmental elements, infections, and lifestyle alterations, such as dietary habits and increased exposure to chemicals. Vyvgart (efgartigimod alfa-fcab) serves as a treatment for autoimmune diseases, specifically generalized myasthenia gravis (gMG), by targeting and inhibiting the neonatal Fc receptor (FcRn) to reduce pathogenic antibodies that contribute to the disease. For instance, data from August 2024, provided by the Myasthenia Gravis Foundation of America, a US-based organization, indicates that myasthenia gravis impacts approximately 150 to 200 individuals per million people worldwide. In the United States, an estimated 37 out of every 100,000 people are affected by this condition. Therefore, the increasing prevalence of autoimmune diseases is a significant driving force behind the vyvgat market.
Vyvgart Market Segmentation: How Does The Market Break Down By Category?
The vyvgart market covered in this report is segmented –
1) By Indication: Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2) By End User: Adult, Geriatric
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Vyvgart Market Trends: What’s Defining The Industry’s Next Phase?
A primary focus within the vyvgart market involves securing regulatory clearances to achieve a competitive advantage. Such endorsements are vital for confirming Vyvgart’s safety and effectiveness when used for autoimmune conditions, boosting the medication’s availability in the market and strengthening trust among medical professionals and those receiving treatment. As an example, in March 2024, argenx, an immunology firm based in the Netherlands, disclosed that its novel therapy, VYVGART (efgartigimod alfa), was approved in Japan for adults experiencing primary immune thrombocytopenia (ITP). This authorization, issued by Japan’s Ministry of Health, Labour and Welfare, represents VYVGART’s initial worldwide recognition specifically for ITP, broadening its treatment uses beyond generalized myasthenia gravis (gMG), for which it had previously gained approval in several areas like the United States and Europe. VYVGART functions as a human IgG1 antibody fragment designed to target the neonatal Fc receptor (FcRn), which results in a decrease of circulating IgG autoantibodies. This mode of action offers a novel therapeutic choice for individuals who have been awaiting effective remedies for this particular autoimmune disorder.
Vyvgart Market Competitive Overview And Top Companies
Major companies operating in the vyvgart market are Argenx SE
View The Full Vyvgart Market Report:
Vyvgart Market Geographic Distribution And Regional Opportunities
North America was the largest region in the vyvgart market in 2025. The regions covered in the vyvgart market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
